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Abstract
Background: Chronic kidney disease (CKD) is an established risk factor for cardiovascular
disease, but the significance of lower Glomerular filtration rate on incidence and mortality from
cancer is uncertain. There is evidence that cancer risk and cancer mortality may be increased in
individuals with End Stage Renal Disease (ESRD) requiring dialysis or after renal transplantation
but whether less severe kidney disease is associated with cancer remains poorly understood.
Some studies indicate that these associations do appear to be organ specific. It has been reported
that reduced renal function is associated with an increased risk of cancers of the kidney and Genitourinary system, gastrointestinal, lung and some soft tissue and hematological cancers like
myeloma.
Objectives: To characterize the Chronic Kidney Disease (CKD) patients by cancer incidents.
Additionally, to calculate the crude and age-adjusted cancer incidence in individuals with
compromised kidney function.
Methods: A retrospective cohort study was conducted using the electronic medical record
information from the patients received treatment at Nebraska Medicine from 2008 to 2018,
extracted by UNMC Public Health Informatics lab. The subjects with Chronic Kidney Disease and
eventually advanced to cancer were included in the study (N=869). The subjects are characterized
by descriptive comparison of age, gender, race, most frequent medical conditions, body mass
index, smoking status, and frequently diagnosed cancer.
Results: The cohort is predominant with Caucasian (n=702; 80.78%) male (n=486; 55.93%)
population with median age 71 (IQR: 63.53). Major proportion of the individuals in the cohort are
obese (n=283; 32.57%). The frequent cancer types among the cohort are digestive (n=129;
3

14.85%), urinary (n=105; 12.08%), respiratory (n=96; 11.05%), skin (n=95; 10.93%) and leukemia
(n=90; 10.36%). The crude/age-adjusted incidence of the frequently observed cancer groups was
exponentially higher than the national, state and the city estimates.

Introduction
Placement site
The Big Data to Knowledge (BD2K) lab, is a part of the UNMC Division of Public Health
Informatics, located at DRC II. Nebraska Medical Center. The research at Big Data to Knowledge
Lab mainly focused on mining patient information from clinical practice, rendering information
into machine-readable formats and analyzing the data using computational techniques to support
clinical care, population health, and analytics. The key focus areas are extracting clinical
information involves capturing information generated from the interaction between the patient and
the healthcare team. Capturing clinical information in a machine-readable format, using SNOMED
CT, RxNORM, and LOINC. Developing machine learning algorithms to generate evidence-based
insights that benefit clinical practice and population health. In response to the patient-centered
outcome research initiative to provide timely answers to the research questions to draw beneficial
health outcomes, the BD2K lab developed clinical data models that retrieve relevant information
from Electronic Health Records.
Problem Statement
There are no evidence-based cancer screening recommendations tailored for patients with Chronic
Kidney Disease. If estimated Glomerular Filtration Rate is associated with an increased risk of
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certain organ-specific cancers, then could this have implications for directing cancer screening
efforts in this select population with Chronic Kidney Disease.
Importance of the project to the organization/clinical community
The capstone activity is a collaboration between Nebraska Medicine and UNMC, wherein the
clinical aspects of the project are initiated by Dr. Apar Ganti (Oncologist) and Dr. Ketki Tendulkar
(Nephrologist), noticed a significant number of patients with compromised renal function are being
diagnosed with cancer over time. So, characterizing and identifying the risks could directly impact
the clinical care of Chronic Kidney Disease patients regarding the frequency and method of cancer
screening aids early detection of cancer.
Purpose and Rationale of the Study:
Majority of the epidemiologic studies are based on the national/state cancer surveillance
database, wherein the information is data rich to calculate the incidence and mortality for specific
cancer type. The cancer surveillance databases often fail to provide patient-related clinical
information. Therefore, the proposed study is utilizing the i2b2 database that contains all the
clinical data that is recorded in the patient’s electronic health record. This includes patient disease
history, medication history, diagnostic test results (histopathology, imaging, genetic tests, organspecific diagnostic profiles) ever conducted during the patient encounter.
The study fills the gaps/possible confounders while evaluating the epidemiologic
association between cancer and Chronic Kidney Disease.
Goals and Objectives:
Aim: To characterize chronic kidney disease (CKD) patient population with different cancer types
at Nebraska Medicine, Omaha, NE, from 2008 to 2018.
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Hypothesis
We hypothesize that there is an increased risk of cancer incidence associated with renal impairment
(dialysis dependent and patients with glomerular filtration rate less than 60 ml/min/1.73 m3).
Literature review
The patients with renal failure are at higher risk to develop cancer and with higher cancer mortality
rate than compared to individuals with optimum kidney function. Multiple population-based
studies conducted to analyze the association between impaired kidney function and cancer have
reported an increased risk associated with thyroid/endocrine, gastrointestinal, hepatobiliary,
urinary tract, kidney cancer and for multiple myeloma and chronic myeloid leukemia.
The incidence pattern across different countries varied, a cohort from Taiwan showed a higher
incidence of bladder cancer (SIR 8.2 95% CI 6.7-9.9) (Lin et al., 2012) and lung cancer compared
to kidney cancer (HR 8.81 95% CI 6.62-11.72) (Chien et al., 2017). Additionally, Kidney cancer
is higher in the United States for both dialysis-dependent patients (OR 2.42 95% CI 2.01-2.92)
(Shebl, Warren, Eggers, & Engels, 2012) and patients with glomerular filtrate rate less than 60
(Christensson et al., 2013; Lowrance, Ordonez, Udaltsova, Russo, & Go, 2014), Australia and New
Zealand (SIR 9.9 95% CI 7.7-12.3) and Europe (SIR 3.3 95% CI 3.1-3.6) (Maisonneuve et al.,
1999). The cohort from Korea showed a higher incidence of urinary tract cancer (SIR 4.7 95% CI
2.42-8.19) (Yoo et al., 2017).
A study based on white Australian cohort identified that risk of cancer death increases by 29%
(mean follow up 10.1 years) and 18% (mean follow up period 12.8 years) for every 10 ml/min/1.73
m3 reduction in estimated Glomerular Filtration Rate, with higher risk associated with lung, breast
and urinary tract cancer deaths among patients with reduced kidney function (Iff et al., 2014; Wong
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et al., 2009). The overall risk assessment of cancer associated with renal impairment remained
inconsistent among literature and geographical locations.
The underlying factor for this observation could be due to genomic instability and genetic damage
in Chronic Kidney Disease patients possibly due to the accumulation of uremic toxins, oxidative
stress mediators and endogenous substances with genotoxic properties. Observation of DNA
damage assessed by comet assay show higher DNA damage in Chronic Kidney Disease patients
(21.42 ± 0.41 %) than controls (7.74 ± 0.41%) (Corredor et al., 2015). Other assays such as alkaline
comet assay and cytokine block micronucleus assay in peripheral blood lymphocytes have also
been used to quantify the DNA and chromosomal damage, and conclude that there is a significant
increase in micronucleus frequency and tail DNA intensity in Chronic Kidney Disease patients
(Rangel-Lopez et al., 2013).
A study based on pediatric population, used comet/enzyme-modified comet assay to determine the
percentage DNA intensity as a measure of genetic damage found and oxidative DNA damage in
formamidopyrimidine DNA glycosylase, is significantly higher in a pediatric group with Chronic
Kidney Disease (Aykanat et al., 2011). A comet assay of biomarkers of DNA damage including
micronuclei, DNA strand breaks found to be higher in Chronic Kidney Disease patients
undergoing dialysis (Schupp, Stopper, & Heidland, 2016).
There is a definitive relationship between kidney function and cancer, in terms of both biological
assays and population-based studies that demonstrated statistically significant correlations.
However, the cancer types across geographical regions varied remarkably.
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Methods
Research question:
Do patients with chronic kidney disease patients have an increased risk of developing cancer?
Study Design
A

single-center

retrospective

population-based

cohort

study

that

includes

patients

diagnosed/treated for Chronic Kidney Disease prior to cancer diagnosis, at Nebraska Medicine
from 2008 to 2018.
Study Population/Study sample/Data sources/ Data collection methods
The cohort predominantly includes Nebraska residents with Chronic Kidney Disease prior to
cancer diagnosis and treated at Nebraska Medicine. For this study, de-identified patient
information retrieved from i2b2, through the BD2K lab maintained by Dr. W. Scott Campbell
M.B.A., Ph.D.
The information retrieved from i2b2 is rich in clinical information as the data is exchanged directly
from the patient’s electronic health record. The probability of data errors is expected to be
decidedly less, as the automated machine algorithms segregate the information from the electronic
health record and involve minimal or no manual data entry during the data exchange.
The de-identified data contain multiple files with a pseudo-patient identification number (primary
key), that is mapped to eGFR test results, clinical diagnoses (SNOMED CT concept codes), body
mass index ever documented for the patient at Nebraska Medicine, date of birth, gender and race.
This allowed me to develop an entity relationship scheme (by one to many or many to one relation)
using MySQL Workbench (Ver. 8.0.12) and Tableau Prep (Ver. 2018.2).
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Fig 1. Extraction of analytic dataset

Systematized Nomenclature of Medicine – Clinical Terms (SNOMED CT) Design:
The SNOMED CT is maintained by the International Health Terminology Standard
Development
Organization
(IHTSDO).
Unlike the
International
Classification
of Diseases,
SNOMED
captures
granular clinical

Fig 2. SNOMED CT hierarchy design
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information from electronic health records. Allows medical practitioners to capture detailed
ontologies and catalog the patient clinical problem list (Bhattacharyya, 2015; SNOMED, 2014).
In the current study, I
included all the
concept codes related
to Chronic kidney
disease and cancers.
The SNOMED CT
contains about 58
Fig 3. Chronic Kidney Disease schematic representation
different classifications of
the parent diagnosis ‘Chronic Kidney Disease’ (SNOMED, 2014).
Additionally, SNOMED CT code descriptions are extracted using Python (Python Version 2.7.14)
Application Programming Interface (API) based on SNOMED English version 20180131
developed by SNOMED international.
Source code (Apache license Ver. 2.0, Jan 2004):
from urllib.request import urlopen
from urllib.parse import quote
import json
baseUrl = 'http://browser.ihtsdotools.org/api/v1/snomed/'
edition = 'en-edition'
version = 'v20180131'
#Prints description of a concept ID
def getConceptById(id):
url = baseUrl + edition + '/' + version + '/concepts/' + id
response = urlopen(url).read()
data = json.loads(response.decode('utf-8'))
10

print (data['fsn'])
getConceptById('XXXXXXXXXX')
Eligibility criterion
Inclusion
•

Subjects with chronic kidney disease and eventually developed cancer.

•

Age of 18 and above, received care at Nebraska Medicine between 2008 and 2018

•

Subjects with at least three estimated Glomerular Filtration Rate results available in a year
before cancer diagnosis.

Exclusion
•

All the subjects diagnosed with secondary and metastatic cancer were excluded.

•

All the individuals underwent a kidney transplant before the date of cancer diagnosis are
excluded.

Case Ascertainment
The i2b2 database contains detailed de-identified patient information who are treated at Nebraska
Medicine.
Measurement of Outcomes
Primary outcome: The primary outcome is to characterize the cohort by age, gender, race by cancer
type and eGFR group.
Abstracted Variables
Age, gender, race, the clinical information includes co-morbidities, month and year of Chronic
Kidney Disease/cancer diagnosis, cancer type, glomerular filtration rate.

Statistical Methods
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The subjects are classified into four estimated Glomerular Filtration Rate groups based on the
average of the latest three eGFR estimate results based on individual patient’s cancer diagnosis
date.
The eGFR grouping is based on Kidney Disease Improving Global Outcomes (KDIGO) 2012
classification and due to smaller sample size, the KIDGO classification is slightly modified
(Bargman & Skorecki, 2018).
The cancer related SnomedCT concept code descriptions are mapped to International
Classification of Disease for Oncology Version 3.0 Topographical codes and the patients are
grouped by primary site of cancer (International Classification of Diseases for Oncology, 2013).
The crude and age-adjusted incidence are calculated for the chronic kidney disease population who
received treatment from Nebraska Medicine. The population proportions for respective age groups
were extracted from US Census Bureau - 2010 Decennial estimates for Omaha (2010 Census
Summary File 1, 2012). Additionally, the age-adjusted incidence is compared with the US,
Nebraska and Omaha-Council Bluffs region. The age-adjusted cancer incidence for US, Nebraska
and Omaha-Council Bluffs was extracted from CDC Wonder – cancer incidence database for the
year 2006 – 2015 including the population of age 20 years and older for comparison (Control &
Prevention, 2008).
The descriptive statistics for the variables age, gender, ethnicity, medical history, body mass index,
smoking history by cancer groups and estimated Glomerular Filtration Rate groups are generated
using SAS software, version 9.4 ("SAS 9.4," 2012). The descriptive statistics and comparison of
proportions for categorical data using Chi-Square or Fisher Exact test, categorical and continuous
data using Kruskal-Wallis test (Burlew, 2005; Cody, 2011).
Results
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A total of 869 subjects are enrolled in the study: 468 male and 383 females with a median age of
71 years (IQR 63.53, 79.52). The subjects are all chronic kidney disease patients who developed
cancer and received patient care at Nebraska Medicine from the year 2008 to 2018.
The

cohort

is

predominant with male
(55.93%)

Caucasians

(80.78%) with a median
age of 71 years (IQR
63.53,

79.52).

median

The

estimated

Glomerular filtration rate
is 51 ml/min/ 1.73 m3
(IQR 37.66, 60) and
majority (36.48%) of the
individuals
estimated

within
glomerular

filtration rate between 45

Classification
All cancer cases
Digestive system
Urinary system
Respiratory system
Skin
Leukemia
Male genital system
Breast
Neoplasm, uncertain whether
benign or malignant
Sarcoma, NOS
Female genital system
Malignant neoplasms of illdefined, other secondary and
unspecified sites
Oral cavity and Pharynx
Neuroendocrine carcinoma,
NOS
Carcinoma in situ, NOS
Endocrine system
Malignant Neoplasm of
Genitourinary Organs
Bone and joint
Brain and other nervous
system
Mesothelioma and soft tissue

Frequency Percent At risk Crude
869
20400 4259.80
129
14.84 20400 632.35
105
12.08 20400 514.71
96
11.05 20400 470.59
95
10.93 20400 465.69
90
10.36 20400 441.18
87
10.01 11240 774.02
66
7.59
20400 323.53
46

5.29

20400

225.49

38
30

4.37
3.45

20400
9160

186.27
327.51

21

2.42

20400

102.94

18

2.07

20400

88.24

11

1.27

20400

53.92

10
10

1.15
1.15

20400
20400

49.02
49.02

9

1.04

20400

44.12

4

0.46

20400

19.61

2

0.23

20400

9.80

2

0.23

20400

9.80

to 50 ml/min/1.73 m3,
which

is

clinically

Table 1. Crude cancer incidence per 100,000

considered as mild to moderately decreased kidney function according to the Kidney Disease
Improving Global Outcome (KDIGO) classification of chronic kidney disease (Bargman &
Skorecki, 2018).
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The most frequent cancer among the cohort are digestive (14.85%), urinary (12.08%), respiratory
(11.05%), skin (10.93%) and leukemia (10.36%). More than half (51.32%) of the subjects in the
cohort developed cancer within a year from clinical diagnosis of chronic kidney disease. The
median time to develop cancer in the cohort is 45 weeks (IQR 3.85, 175.28) post clinical diagnosis
of chronic kidney disease.
Age
Standard
distribution
Cohort
Population of a standard population
population
Age
group
18 - 59
60 - 69
70 - 79
80+
Total

240074
33177
18947
14089
306287

0.783820404
0.108319974
0.061860281
0.04599934
1

5108
4192
4933
6167
20400

cancer

2286.40
625.32
342.34
152.91
3406.97

Digestive Urinary Respiratory
System System
System

245.52
87.85
57.68
24.61
415.67

322.24
77.52
36.37
18.65
454.78

214.83
67.18
42.64
16.41
341.06

Skin
cancer

Leukemia

306.90
62.02
38.87
14.92
422.71

306.90
51.68
33.86
20.14
412.58

Standard population estimates retrieved from US Census Bureau 2010 Decennial census for Omaha
Table 2. Age-adjusted cancer incidence per 100,000
The overall crude and age-adjusted cancer incidence among chronic kidney disease patients are
exponentially high compared to the country (US), state (Nebraska) and city (Omaha / CouncilBluffs region). The overall cancer incidence in chronic kidney disease patients is about five times
higher than the national average with an incidence rate of 3406.97 per 100,000 population.
The incidence of digestive cancer in chronic kidney disease patients is 3 times higher (415.67 per
100,000 population), urinary system cancers are 23 times higher (415.58 per 100,000 population),
respiratory cancer 3 times (314.06 per 100,000 population), skin cancers 13 times higher (422.71
per 100,000) and leukemia 23 times higher (412.58 per 100,000 population) than the US national
average.
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Fig 4. Age-adjusted incidence comparison
About 40 % of the of the cancer types include male genital (n=87; 10.01%), breast (n=66; 7.59%),
neoplasms (uncertain whether benign or malignant) (n=46; 5.29%), sarcoma (n=38; 4.37%),
female genital (n=30; 3.45%), malignant neoplasms (n=21; 2.42%), oral cavity/pharynx (n=18;
2.07%), neuroendocrine carcinoma (n=11; 1.27%), carcinoma in-situ (n=10; 1.15%), endocrine
n=10; 1.15%), malignant neoplasm of genitourinary tract (n=9; 1.04%), bone/joint (n=4; 0.46%),
brain/other nervous system and mesothelioma/soft tissue with 2 (0.23%) cases in each category.
All the subjects in the cohort are with at least one or more active clinical diagnosis of chronic
disease. The most frequent chronic disease conditions among the cohort are anemia (44.99%),
depression (22.78%), diabetes (38.09%), gastroesophageal reflux disease (GERD) (27.85%), heart
failure (24.84%), hypertension (82.28%) and hyperlipidemia (46.49%).
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Major proportion of the individuals in the cohort are in age group of 70 to 79 years (n=273;
31.42%) and 60 to 69 years (n=242; 27.85%), but age distribution do not have statistical
differences among different cancer groups (chi-square = 22.6654, df=21, P=0.3621). Even the
median age among cancer groups is not statistically different (Kruskal Wallis = 4.3668, df=7,
P=0.7367). In contrast, the frequency of subjects in terms of gender and ethnicity are statistically
different among cancer groups. The gender being male has higher number of cancers: digestive
(n=69; 7.94%), urinary (n=75; 8.63%), respiratory (n=47; 5.41%), skin cancer (n=60; 6.9%) and
leukemia (n=61; 7.02) (chi-square = 13.6324, df=7, P<0.0001). The distribution of cancer patients
across different ethnic groups has statistical differences, wherein whites with higher proportion
across cancer types: digestive (n=95; 10.93%), urinary (n=84; 9.67%), respiratory (n=77; 8.86%),
skin (n=90; 10.36%) and leukemia (n=83; 9.55%) (chi-square = 35.1004, df=14, P=0.0014).
The information on body mass index (BMI) is missing for 36 individuals and the cohort while
classified according to the National Institute of Health, National Heart, Lung and Blood Institute
(NHLBI) BMI index (Kushner, 2018), majority (n=283; 32.57%) of the individuals are obese and
the distribution is statistically different compared to normal weight (n=238; 27.38%), overweight
(n=240; 27.62%) and extremely obese (n=72; 8.29%). While the frequencies across cancer types
varied from overall cancer, major proportion of individuals with normal weight in digestive (n=49;
5.64%), obese in urinary (n=41; 4.72%) / leukemia (n=33; 3.80%) and overweight in respiratory
(n=32; 3.68%) / skin (n=33; 3.80%) (chi-square = 54.2503, df=28, P=0.0021).
In contrast, when the BMI considered as a continuous variable there was no statistical difference
observed among the cancer groups, the median BMI among cancer groups are: digestive 27 (IQR
23.09, 31.87), urinary 28 (25.29, 33.82), respiratory 27 (23.39, 31.84), skin 27 (24.19, 31.63) and
leukemia 28 (24.56, 31.7) (Kruskal Wallis = 10.4428, df=7, P=0.1648).
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There are no statistical differences in patients with anemia (chi-square = 5.8739, df=7, P=0.5545),
depression (chi-square = 2.0595, df=7, P=0.9582), diabetes (chi-square = 10.462, df=7, P=0.1639),
GERD (chi-square = 7.2363, df=7, P=0.4047), heart failure (chi-square = 4.1677, df=7, P=0.7603),
hypertension (chi-square = 13.4567, df=7, P=0.0617) and hyperlipidemia (chi-square = 11.4824,
df=7, P=0.1189) across different cancer groups.
To estimate the impact of kidney function to cause cancer, estimated Glomerular Filtration Rate is
used as a surrogate, but there are no statistical differences between estimated glomerular filtration
rate groups and cancer. A major proportion of the cancer incidents were noticed in patients with
mild/mild to moderate kidney dysfunction (n=553; 63.63%) compared to individuals with
moderate / severe kidney problem (n= 316; 36.36%) (Chi-Square = 15.4484, df=21, P=0.7998).
The median estimated Glomerular Filtration Rate did not have statistical differences among cancer
types: digestive 51 (IQR 36.66, 60), urinary 47 (37.66, 55.33), respiratory 53 (40, 60), skin 53 (44,
60) and leukemia 52 (36.66, 60) (Kruskal Wallis = 9.4029, df=7, P=0.2250). The median estimated
Glomerular Filtration Rate among all the cancer types could be classified as KDIGO G3a stage
mild to moderate kidney dysfunction (Bargman & Skorecki, 2018).
There were statistically significant differences in the median age with change in clinical kidney
function: severe dysfunction (65, IQR: 59.42, 75.38), moderate to severe dysfunction (77, IQR:
67.84, 82.85), mild to moderate dysfunction (72, IQR: 64.72, 80.65) and mild dysfunction (70,
IQR: 61.69, 76.81) (Kruskal Wallis = 38.99, df=3, P < 0.001). The distribution of subjects based
on kidney function among age groups was statistically different (Chi-Square= 32.72, df=9, P <
0.001). Among the individuals with severe kidney dysfunction, majority of the subjects were
within the age group of 60 – 60 years (n=44; 5.06%) and the age groups 70 – 79 years was higher
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among moderate to severe dysfunction (n=65; 7.48%), mild to moderate dysfunction (n=98;
11.28%) and mild dysfunction (n=80; 9.21%).
The subject’s gender (Chi-Square=6.48, df=3, P = 0.09) and BMI (Chi-Square=14.89, df=12, P =
0.2473) do not have statistical differences among individuals with changes in kidney function. The
median BMI among individuals with change in kidney function did not have statistical differences
(Kruskal-Wallis= 1.3054, df=3, P = 0.7279). The median BMI in severe dysfunction is 27 (IQR:
22.93, 33.03), moderate to severe dysfunction 27 (IQR: 23.94, 33.36), mild to moderate
dysfunction 28 (IQR: 24.27. 34.11) and mild dysfunction 28 (IQR: 23.81, 32.45). According to
the NHLBI BMI scale based on the median BMI, all the subjects could be classified as overweight
(Kushner, 2018). The ethnic group being Caucasians (n=702; 80.78%) was predominant in the
cohort and even across different kidney function categories: severe dysfunction (n=91; 10.47%),
severe to moderate dysfunction (n=153; 17.61%), mild to moderate dysfunction (n=262; 30.15%)
and mild dysfunction (n=196; 22.55%) which was statistically different compared to the other
ethnicities (Chi-Square= 16.98, df=6, P = 0.0093).
The chronic medical conditions anemia (Chi-Square= 22.3259, df=3, P < 0.001) and GERD (ChiSquare= 8.1441, df=3, P = 0.0431) are statistical different among kidney function groups. The
spread of anemia across individuals with mild to moderate dysfunction with a higher proportion
(n=137; 15.77%) and followed by moderate to severe dysfunction (n=94; 10.82%), mild
dysfunction (n=84; 9.67%), severe dysfunction (n=76; 8.75%). The GERD condition among mild
to moderate dysfunction (n=103; 11.85%) is higher and mild dysfunction (n=60; 6.9%), moderate
to severe dysfunction (n=41; 4.72%) and severe dysfunction (n=38; 4.37%).
The remaining chronic conditions did not differ with change in kidney function: depression (ChiSquare= 0.3931, df=3, P = 0.9417), diabetes (Chi-Square= 3.9309, df=3, P = 0.269), heart failure
18

(Chi-Square= 3.8074, df=3, P = 0.3607), hypertension (Chi-Square= 4.0886, df=3, P = 0.521) and
hyperlipidemia (Chi-Square= 1.5287, df=3, P = 0.6757).
The median time in weeks to develop cancer among individuals with a change in kidney function
was not statistically different (Kruskal-Wallis= 0.0969, df=3, P = 0.9922). The median duration in
weeks to develop cancer is narrow among individuals with severe dysfunction (45, IQR: 3.85,
175.28) and almost similar among moderate to severe dysfunction (49, IQR: 8.28, 164.28), mild
to moderate dysfunction (48, IQR: 5.71, 137.71) and mild dysfunction (49, IQR: 3.21, 138.21).
Additionally, active smoking or smoking history is a major confounding factor associated with
cancer development; there are 17 (1.96%) individuals in the cohort.
Discussion
In the current study all the Chronic Kidney Disease patients who eventually developed cancer were
included, taking into consideration that the individuals could be with the underlying impaired
kidney function before clinically diagnosed as Chronic Kidney Disease.
As hypothesized, the risk of cancer in Chronic Kidney Disease patients was high, and the ageadjusted incidence rate among the cohort was exponentially higher, compared to the National (US),
state (Nebraska) and city (Omaha-Council Bluffs region). The cancer incidence is predominant in
elderly (median age 71 years; IQR: 63.53, 79.52) male (n=486; 55.93%) Caucasians (n=702;
80.78%). The dominance in elderly could be due to the genetic changes due to aging, the changes
in nuclear DNA could alter mutations, chromosomal aneuploidy, copy number variations and
telomere shortening (Cabo & Couteur, 2018). In terms of gender, the alterations in genetics due to
hormonal differences and molecular changes in male physiology could trigger cancer development
(Kim, Lim, & Moon, 2018). Assuming that majority of the individuals receive care at Nebraska
19

Medicine from closer proximity, the ethnic variation could be due to the proportion of Caucasians
(73.1%) in Omaha, NE (2010 Census Summary File 1, 2012).
The cohort contains statistical differences in BMI groups, but the median BMI across different
cancer groups did not flag some differences. This could be due to the classification of individuals
with a borderline BMI into specific groups. Based on the median BMI among the frequent cancer
types, the subjects could be classified as overweight. The reason behind overweight consistent
among all the cancer types could be due to the reason that visceral adipose tissue which plays a
crucial role in producing proinflammatory cytokines. The induction of inflammatory process
activates nuclear factor Kappa B (NF-kB) and signal transducer and activation of transcription 3
(STAT3). The NF-kB is a transcription factor has a potential to induce expression of protein
structures associated with pro-inflammatory, proliferative and repetitive pathways (Jacob,
Varghese, & Weil, 2018).
The most frequent comorbidities in the cohort, anemia is related to the underlying Chronic Kidney
Disease condition. In progressive Chronic Kidney Disease condition, the patients fail to produce
erythropoietin and reduction in red blood cell survival usually progress to hypo-proliferative
anemia, and it is associated with the clinical stage of Chronic Kidney Disease. The chance of a
Chronic Kidney Disease patient to develop anemia would multiply in individuals with diabetes
(Adamson, 2018). Similarly, the subjects in the cohort have statistical differences with a change
in kidney function.
Additionally, chronic medical conditions such as hypertension, hyperlipidemia, heart failure, and
diabetes increase the risk of cancer incidence (Tu et al., 2018). The cardiovascular diseases alter
hemodynamic and neurohormonal factors that trigger increased reactive oxygen species, altered
cardiac gene expression, increases oxidative stress, myocyte necrosis and apoptosis (Helmut
20

Drexler, 2010). The collective factors increase mutagen sensitivity, DNA damage (Federici et al.,
2015). The patients with type 2 diabetes have increased production of reactive oxygen species,
reduced antioxidant withhold capacity, and susceptible to DNA damage (Lee & Chan, 2015).
The literature did not support evidence for a specific cancer type, and similarly, the results from
the cohort did not have statistical differences of cardiovascular diseases or diabetes across cancer
types.
As tobacco smoking is a significant factor associated with cancer incidence, the electronic medical
record information on tobacco smoking is documented for 17 individuals. I feel that the lower
proportion of the smokers in the cohort could be due to under-reporting of medical information in
the health records.
Based on the literature, impaired kidney function is associated to cause oxidative stress due to
Vitamin C deficiency, reduced Vitamin E, compromised glutathione system and increased prooxidant activity due to aging, chronic inflammatory status. The oxidative stress and increased prooxidant activity upon interaction with inflammatory stimuli, oxidant-free radicals are generated by
phagocytic cells (Locatelli et al., 2003). The Chronic Kidney Disease patients often present with
genomic instability, due to extensive genetic damage caused by a toxin and endogenous genotoxin
accumulation (Rangel-Lopez et al., 2013). The genotoxic effect could lead to loss of chromosomal
fragments or entire chromosomes, this could lead to the formation of micronuclei upon cell
division. The cytokinesis-block micronucleus assay and comet assay revealed chromosomal
abnormalities, reduced DNA repair and DNA lesions in Chronic Kidney Disease patients. But the
population-based studies are inconsistent in stratifying the risk to a specific cancer type (Roth et
al., 2008; Schupp et al., 2016).

21

The cancer incidence from the cohort did not have statistical differences among estimated
Glomerular Kidney Function groups. Based on the median estimated Glomerular Filtration Rate
among the cancer groups, the overall cohort could be classified as mild to moderate kidney
dysfunction.
Limitations: The study could not be generalized to a country-wide scale, as the samples are not
randomly selected. Due to age group stratification which did not precisely match the age groups
from the cancer database the incidence comparison group (US, Nebraska and Omaha-Council
Bluffs region) is missing with the incidence information for the individuals of age 18 years.
Recommendations for future projects:
The current work is a preliminary analysis of the planned research. The study will be extended to
identify the role of drug exposures, time to cancer analysis and estimating hazard proportion ratio
among different cancer groups.
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Capstone Experience Reflection:
•

My capstone activity is a collaboration with Public Health Informatics Lab, UNMC DRC
– II. At Public Health Informatics Lab, Dr. Campbell and team maintained a clinical data
warehouse called i2b2 (Informatics for integrating Biology & the Bedside), based on the
de-identified patient electronic medical records who received care services at Nebraska
Medicine.

•

The organization is multi-disciplinary, combination of health care and data science experts
to maintain and execute queries to develop evidence-based medicine insights.

•

The capstone opportunity is my first-hand experience to handle electronic health record
information at a larger volume.

•

The tasks related to the capstone allowed me to gain detailed understanding on SNOMED
CT coding and cross mapping to the ICD codes.

•

It’s an intense exercise for me to use SQL and data mining strategies.

•

The planned activity trained me to be a liaison between clinical and data science teams in
parallel.

•

Additionally, I gained experience on critical thinking related to epidemiological and
statistical application in real time research.
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